These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1726 related items for PubMed ID: 24286461

  • 1. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [Abstract] [Full Text] [Related]

  • 2. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [Abstract] [Full Text] [Related]

  • 3. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Dajti E, Frazzoni L, Iascone V, Secco M, Vestito A, Fuccio L, Eusebi LH, Fusaroli P, Rizzello F, Calabrese C, Gionchetti P, Bazzoli F, Zagari RM.
    Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1120-1131. PubMed ID: 37823411
    [Abstract] [Full Text] [Related]

  • 4. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.
    An YK, Prince D, Gardiner F, Neeman T, Linedale EC, Andrews JM, Connor S, Begun J.
    Med J Aust; 2019 Nov; 211(10):461-467. PubMed ID: 31680263
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z, Clark N, Park KT.
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
    [Abstract] [Full Text] [Related]

  • 6. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT, Hien NM, Dung NT, Quang DM, Vinh NT, Tu TT, Chi TK, Phuong LB, Nhan NT.
    Med Arch; 2024 Feb; 78(2):105-111. PubMed ID: 38566874
    [Abstract] [Full Text] [Related]

  • 7. Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome.
    Chowdhury MFK, Ghosh CK, Miah MSA, Uddin MA, Rassell M, Rashid MH, Pal AK, Mahabub-Uz-Zaman K, Saha KP, Miah MAR.
    Mymensingh Med J; 2024 Oct; 33(4):1149-1156. PubMed ID: 39351737
    [Abstract] [Full Text] [Related]

  • 8. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [Abstract] [Full Text] [Related]

  • 9. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P.
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [Abstract] [Full Text] [Related]

  • 10. Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists.
    Elnawsra O, Fok I, Sparrow M, Gibson P, Andrews J, Connor S.
    Intern Med J; 2016 May; 46(5):590-5. PubMed ID: 26946938
    [Abstract] [Full Text] [Related]

  • 11. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [Abstract] [Full Text] [Related]

  • 12. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [Abstract] [Full Text] [Related]

  • 13. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R, Al M, Corro Ramos I, Deshpande SN, Armstrong N, Lee YC, Ryder S, Noake C, Krol M, Oppe M, Kleijnen J, Severens H.
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [Abstract] [Full Text] [Related]

  • 14. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G.
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [Abstract] [Full Text] [Related]

  • 15. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care.
    Conroy S, Hale MF, Cross SS, Swallow K, Sidhu RH, Sargur R, Lobo AJ.
    J Clin Pathol; 2018 Apr; 71(4):316-322. PubMed ID: 28844038
    [Abstract] [Full Text] [Related]

  • 16. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A.
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [Abstract] [Full Text] [Related]

  • 17. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ, Ford C, Gama RM, Ali A, McKaig B, Waldron JL, Steed H, Brookes MJ.
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [Abstract] [Full Text] [Related]

  • 18. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F.
    World J Gastroenterol; 2018 Sep 07; 24(33):3681-3694. PubMed ID: 30197475
    [Abstract] [Full Text] [Related]

  • 19. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ, Sydora BC, Fedorak RN.
    J Crohns Colitis; 2012 Mar 07; 6(2):207-14. PubMed ID: 22325175
    [Abstract] [Full Text] [Related]

  • 20. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP, Zierold C, Rode AM, Blocki FA, Vaughn BP.
    J Clin Gastroenterol; 2021 Mar 01; 55(3):239-243. PubMed ID: 32324678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 87.